-
Coherus BioSciences, Inc. (NASDAQ: CHRS)
Coherus (Nasdaq: CHRS) is focused on developing and commercializing a diversified portfolio of next-generation immune-oncology therapies and combinations that potentially extend patient survival across tumor types. The company’s recent U.S. FDA approval of LOQTORZI (toripalimab-tpzi) for nasopharyngeal carcinoma, and its multiple clinical-stage immuno-oncology candidates targeting the tumor microenvironment, underscore Coherus’s commitment to innovation in immuno-oncology while the established infrastructure of its biosimilars business enables better treatment options, access, and outcomes for patients with life-altering diseases.
Dennis M. Lanfear
CEO
Denny Lanfear is a biopharmaceutical leader with a proven track record of successful entrepreneurial vision and achievement. In 2010, after decades working in the biopharmaceutical industry, he founded Coherus BioSciences with the vision of improving the public’s access to high-quality, life-changing medicines. A dedicated entrepreneur, Mr. Lanfear founded two other companies before Coherus BioSciences: Saronyx, Inc., a drug development software services company and the biopharmaceutical company InteKrin Therapeutics. He served as CEO of both firms. Earlier in his career, Mr. Lanfear held senior leadership roles at Amgen Inc., integrating more than 2,500 operations and staff worldwide after the company’s explosive growth. Mr. Lanfear currently serves on the board of directors of NEUVOGEN, Inc. He holds B.S. degrees in Chemical Engineering and Biochemistry from Michigan State University and an M.B.A. from the Anderson School of Management at the University of California, Los Angeles.